How Acute Kidney Injury Is Staged, and Why It Is Not the Same as CKD

Acute kidney injury (AKI) is staged one to three by how far a person's serum creatinine rises above their own baseline and how long their urine output stays low, using thresholds that the KDIGO 2012 clinical practice guideline standardized. Chronic kidney disease (CKD) is a different diagnosis entirely: it describes abnormalities of kidney structure or function that persist for at least three months, and it is graded by filtration rate and albuminuria rather than by an abrupt jump. The two share the word "kidney" and often the same creatinine number, yet they sit on opposite ends of a clock. One is sudden and frequently reversible; the other is durable and tracked over years, and that difference in tempo is the reason clinicians appraise them through separate systems.

What KDIGO actually standardized

Before 2012, two competing frameworks described sudden kidney dysfunction. The RIFLE criteria arrived in 2004, and the AKIN criteria followed in 2007, each with slightly different cutoffs and time windows. That fragmentation made studies hard to compare. The KDIGO 2012 guideline merged the two into a single definition, which is now the common reference point for research and bedside classification, as recent peer-reviewed appraisals of AKI methodology describe.

Under KDIGO, AKI is present if any one of three things happens: serum creatinine rises by at least 0.3 mg/dL (26.5 micromol/L) within 48 hours; serum creatinine climbs to at least 1.5 times a known or presumed baseline within the prior seven days; or urine volume falls below 0.5 mL/kg/h for six hours. Two of those criteria are anchored to time windows, and that is deliberate. AKI is defined by change, not by a single absolute value, so the definition insists on knowing where the number started and how fast it moved.

The staging table

Once AKI is diagnosed, KDIGO grades its severity in three stages, and a patient is placed at whichever stage their worst finding reaches, whether that finding is the creatinine value or the urine output.

• Stage 1: creatinine 1.5 to 1.9 times baseline, or a rise of at least 0.3 mg/dL; or urine output below 0.5 mL/kg/h for six to twelve hours.
• Stage 2: creatinine 2.0 to 2.9 times baseline; or urine output below 0.5 mL/kg/h for twelve hours or more.
• Stage 3: creatinine 3.0 times baseline, or a rise to at least 4.0 mg/dL, or the start of kidney replacement therapy (dialysis); or urine output below 0.3 mL/kg/h for 24 hours or more, or no urine at all for twelve hours.

Notice that stage 3 can be reached by a treatment decision. Starting dialysis defines the most severe stage regardless of the creatinine trajectory, because the need for that intervention is itself a marker of how far function has fallen.

Two clocks running at once

The staging system leans on two different signals because they carry different information. Serum creatinine is a lagging indicator. It reflects a balance between production and clearance, and it takes time to accumulate after filtration drops, so a creatinine that still looks acceptable can understate an injury already underway. Urine output is closer to a real-time functional readout, which is why the oliguria thresholds tighten as the stages climb. Tracking both reduces the chance that a slow-rising creatinine masks a kidney that has, for practical purposes, already stopped keeping up.

Why AKI is not CKD

The cleanest way to separate the two is by duration. AKI is defined within hours to days. CKD, by the KDIGO definition, requires abnormalities of kidney structure or function that have been present for more than three months, with implications for health. CKD is then classified by cause, by glomerular filtration rate in categories G1 through G5, and by albuminuria in categories A1 through A3, a scheme often abbreviated CGA. That structure is built for the long view: it is designed to estimate the risk of progression and complications over years, not to capture a swing over a weekend.

This is also why a single lab result can be genuinely ambiguous. One elevated creatinine, read in isolation, cannot tell you whether it represents a new injury or a stable chronic baseline. The answer comes from trajectory and history, not from the number alone. To bridge the space between the two, the field also recognizes acute kidney disease, a category for changes that fall short of the three-month chronic threshold but extend beyond the abrupt AKI window. And the relationship runs in both directions: an episode of AKI raises the later risk of CKD, while established CKD makes the kidneys more vulnerable to acute insults.

Why the two are appraised differently

Staging AKI answers an urgent question: how severe is this right now, and where is it heading in the next hours and days? That framing drives immediate decisions about fluids, avoiding nephrotoxic exposures, adjusting medication doses, and whether dialysis is warranted. Higher AKI stages are associated with worse short-term outcomes, so the grade is a trigger for action on a compressed timeline.

CKD staging answers a slower question: over the coming months and years, how likely is this person to progress, to accumulate cardiovascular risk, and to need long-term planning? Its categories are prognostic tools for chronic management, from blood pressure targets to drug dosing to timing of specialist referral. Reversibility assumptions differ too. AKI is approached as potentially recoverable, so the emphasis is on rescuing function; CKD is approached as durable, so the emphasis is on slowing decline. Applying one system's logic to the other would misread the tempo of the disease, which is exactly the mistake the separate frameworks exist to prevent.

This article is educational and is not medical advice; decisions about kidney testing or treatment belong with a qualified clinician who knows the individual case.